Literature DB >> 18490458

Cathelicidin LL-37 in severe Streptococcus pyogenes soft tissue infections in humans.

Linda Johansson1, Pontus Thulin, Parham Sendi, Erika Hertzén, Adam Linder, Per Akesson, Donald E Low, Birgitta Agerberth, Anna Norrby-Teglund.   

Abstract

Severe soft tissue infections, such as necrotizing fasciitis and severe cellulitis, caused by group A streptococci (GAS) are rapidly progressing life-threatening infections characterized by massive bacterial loads in the tissue even late after the onset of infection. Antimicrobial peptides are important components of the innate host defense, and cathelicidins have been shown to protect against murine necrotic skin infections caused by GAS. However, it has been demonstrated that the streptococcal cysteine protease SpeB proteolytically inactivates the human cathelicidin LL-37 in vitro. Here we have investigated the expression of LL-37 and its interaction with GAS and SpeB during acute severe soft tissue infections by analyses of patient tissue biopsy specimens. The results showed large amounts of LL-37, both the proform (hCAP18) and the mature peptide, in the tissue. Confocal microscopy identified neutrophils as the main source of the peptide. A distinct colocalization between the bacteria and LL-37 could be noted, and bacterial loads showed positive correlation to the LL-37 levels. Areas with high LL-37 levels coincided with areas with large amounts of SpeB. Confocal microscopy confirmed strong colocalization of GAS, SpeB, and LL-37 at the bacterial surface. Taken together, the findings of this study provide in vivo support of the hypothesis that SpeB-mediated inactivation of LL-37 at the streptococcal surface represents a bacterial resistance mechanism at the infected tissue site in patients with severe GAS tissue infections.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18490458      PMCID: PMC2493236          DOI: 10.1128/IAI.01392-07

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  20 in total

1.  The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations.

Authors:  B Agerberth; J Charo; J Werr; B Olsson; F Idali; L Lindbom; R Kiessling; H Jörnvall; H Wigzell; G H Gudmundsson
Journal:  Blood       Date:  2000-11-01       Impact factor: 22.113

2.  Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A Streptococcus.

Authors:  R A Dorschner; V K Pestonjamasp; S Tamakuwala; T Ohtake; J Rudisill; V Nizet; B Agerberth; G H Gudmundsson; R L Gallo
Journal:  J Invest Dermatol       Date:  2001-07       Impact factor: 8.551

3.  Innate antimicrobial peptide protects the skin from invasive bacterial infection.

Authors:  V Nizet; T Ohtake; X Lauth; J Trowbridge; J Rudisill; R A Dorschner; V Pestonjamasp; J Piraino; K Huttner; R L Gallo
Journal:  Nature       Date:  2001-11-22       Impact factor: 49.962

4.  SIC, a secreted protein of Streptococcus pyogenes that inactivates antibacterial peptides.

Authors:  Inga-Maria Frick; Per Akesson; Magnus Rasmussen; Artur Schmidtchen; Lars Björck
Journal:  J Biol Chem       Date:  2003-03-05       Impact factor: 5.157

5.  Evidence for superantigen involvement in severe group a streptococcal tissue infections.

Authors:  A Norrby-Teglund; P Thulin; B S Gan; M Kotb; A McGeer; J Andersson; D E Low
Journal:  J Infect Dis       Date:  2001-08-15       Impact factor: 5.226

6.  Proteinases of common pathogenic bacteria degrade and inactivate the antibacterial peptide LL-37.

Authors:  Artur Schmidtchen; Inga-Maria Frick; Emma Andersson; Hans Tapper; Lars Björck
Journal:  Mol Microbiol       Date:  2002-10       Impact factor: 3.501

7.  Perturbation of the hydrophobic core of lipid bilayers by the human antimicrobial peptide LL-37.

Authors:  Katherine A Henzler-Wildman; Gary V Martinez; Michael F Brown; A Ramamoorthy
Journal:  Biochemistry       Date:  2004-07-06       Impact factor: 3.162

Review 8.  Cathelicidins and innate defense against invasive bacterial infection.

Authors:  Victor Nizet; Richard L Gallo
Journal:  Scand J Infect Dis       Date:  2003

9.  Viable group A streptococci in macrophages during acute soft tissue infection.

Authors:  Pontus Thulin; Linda Johansson; Donald E Low; Bing S Gan; Malak Kotb; Allison McGeer; Anna Norrby-Teglund
Journal:  PLoS Med       Date:  2006-03       Impact factor: 11.069

10.  LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells.

Authors:  Q Chen; A P Schmidt; G M Anderson; J M Wang; J Wooters; J J Oppenheim; O Chertov
Journal:  J Exp Med       Date:  2000-10-02       Impact factor: 14.307

View more
  37 in total

Review 1.  Bacterial resistance mechanisms against host defense peptides.

Authors:  Tomaz Koprivnjak; Andreas Peschel
Journal:  Cell Mol Life Sci       Date:  2011-05-11       Impact factor: 9.261

2.  Dead bacterial absorption of antimicrobial peptides underlies collective tolerance.

Authors:  Fan Wu; Cheemeng Tan
Journal:  J R Soc Interface       Date:  2019-02-28       Impact factor: 4.118

Review 3.  The detrimental impact of extracellular bacterial proteases on wound healing.

Authors:  Sharon Lindsay; Angela Oates; Katie Bourdillon
Journal:  Int Wound J       Date:  2017-07-25       Impact factor: 3.315

4.  Polymorphisms in regulator of protease B (RopB) alter disease phenotype and strain virulence of serotype M3 group A Streptococcus.

Authors:  Randall J Olsen; Daniel R Laucirica; M Ebru Watkins; Marsha L Feske; Jesus R Garcia-Bustillos; Chau Vu; Concepcion Cantu; Samuel A Shelburne; Nahuel Fittipaldi; Muthiah Kumaraswami; Patrick R Shea; Anthony R Flores; Stephen B Beres; Maguerite Lovgren; Gregory J Tyrrell; Androulla Efstratiou; Donald E Low; Chris A Van Beneden; James M Musser
Journal:  J Infect Dis       Date:  2012-01-18       Impact factor: 5.226

5.  Dynamics of speB mRNA transcripts in Streptococcus pyogenes.

Authors:  Zhiyun Chen; Andreas Itzek; Horst Malke; Joseph J Ferretti; Jens Kreth
Journal:  J Bacteriol       Date:  2012-01-20       Impact factor: 3.490

6.  The globally disseminated M1T1 clone of group A Streptococcus evades autophagy for intracellular replication.

Authors:  Timothy C Barnett; David Liebl; Lisa M Seymour; Christine M Gillen; Jin Yan Lim; Christopher N Larock; Mark R Davies; Benjamin L Schulz; Victor Nizet; Rohan D Teasdale; Mark J Walker
Journal:  Cell Host Microbe       Date:  2013-12-11       Impact factor: 21.023

7.  Streptococcal inhibitor of complement promotes innate immune resistance phenotypes of invasive M1T1 group A Streptococcus.

Authors:  Morgan A Pence; Suzan H M Rooijakkers; Anna L Cogen; Jason N Cole; Andrew Hollands; Richard L Gallo; Victor Nizet
Journal:  J Innate Immun       Date:  2010-09-01       Impact factor: 7.349

8.  Biofilm in group A streptococcal necrotizing soft tissue infections.

Authors:  Nikolai Siemens; Bhavya Chakrakodi; Srikanth Mairpady Shambat; Marina Morgan; Helena Bergsten; Ole Hyldegaard; Steinar Skrede; Per Arnell; Martin B Madsen; Linda Johansson; Julius Juarez; Lidija Bosnjak; Matthias Mörgelin; Mattias Svensson; Anna Norrby-Teglund
Journal:  JCI Insight       Date:  2016-07-07

9.  Decreased necrotizing fasciitis capacity caused by a single nucleotide mutation that alters a multiple gene virulence axis.

Authors:  Randall J Olsen; Izabela Sitkiewicz; Ara A Ayeras; Vedia E Gonulal; Concepcion Cantu; Stephen B Beres; Nicole M Green; Benfang Lei; Tammy Humbird; Jamieson Greaver; Ellen Chang; Willie P Ragasa; Charles A Montgomery; Joiner Cartwright; Allison McGeer; Donald E Low; Adeline R Whitney; Philip T Cagle; Terry L Blasdel; Frank R DeLeo; James M Musser
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

10.  Protein C inhibitor--a novel antimicrobial agent.

Authors:  Erik Malmström; Matthias Mörgelin; Martin Malmsten; Linda Johansson; Anna Norrby-Teglund; Oonagh Shannon; Artur Schmidtchen; Joost C M Meijers; Heiko Herwald
Journal:  PLoS Pathog       Date:  2009-12-18       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.